Future-Proof Your CDMO

CDMO_campaign_hero_v4-sm

Learn How to Use Data Analytics To Improve Processes and Generate Revenue for your CDMO

Growing competition and the trend toward digitalization in the biopharma industry means that in order to keep up, you need to leverage your CDMO's most important asset: data.

Leveraging your data can help you realize:

  • Quality and Regulatory Assurance through enhanced process understanding and control
  • Increased Partner Trust through increased external collaboration and process transparency
  • Maximized Revenue through COGs optimization and accelerated delivery times

 

Watch this recent webinar to uncover a competitive advantage

Webinar How Data Analytics can Boost the Bottom Line at a CDMO_38.47

 

ROI Calculator

Discover how much revenue data analytics could generate.

bar-graph

Try the ROI Tool

CDMO Insights

Get the email series to learn more

How Can CDMOs Unlock the Value of Data?

Data is the new oil. However, just like oil, data needs to be refined and properly put to work. Sartorius Data Analytics is the leading provider of advanced data analytics solutions to the biopharmaceutical industry. Our data refinement offerings include MODDE®, for design of experiments, SIMCA® for multivariate data analysis, and SIMCA®-online for real-time process monitoring.

Get a 30-day Free Trial

DOE Artboard-02

Read More

MVDA Cube Artboard-01

Read More

MVDA Sol_artboard-01

Read More

Book a Free Strategy Session to Learn More

Achieving profitability, growth and staying ahead of competitors means leveraging one of your most important assets: data. As the CDMO market consolidates and becomes more competitive, those who tap into the real value of data can use it to gain recognition as strategic differentiators, provide market leadership, and ultimately become more profitable.

Book a 30 minute strategy session

You will learn:

magnifier

How to leverage your data  to secure long-time strategic partnerships

 

order-invoiced

How data can be used to maximize profitability

clock

How data can be used to speed up timelines and accelerate delivery

FUJIFILM-thumbnail-story-en-B-00119-Sartorius

Customer Case Story

In this publication, FUJIFILM discusses how SIMCA® and SIMCA®-online can be leveraged to accelerate chromatography review for faster and more reliable operations. FUJIFILM Diosynth Biotechnologies also uses SIMCA®-online as a portal for their customers to have full transparency into their processes.

Download Case Story

 

Piramal

Poster

Use of Design of Experiments to Define Manufacturing Process Conditions for an ADC

This poster by Piramal Pharma Solutions describes the use of MODDE® Design of Experiments to determine robust setpoints for the reactive stages of an Antibody-Drug Conjugate (ADC) process.

Download Poster

 

Abzena

Development of an ADC Process with Single-Use Membrane Technology

This poster by Abzena shows how MODDE® Design of Experiments can be used to optimize membrane chromatography screening and scale-up for an Antibody Drug Conjugate (ADC) process.

Download Poster

 

 

Read More From Our Blog

CDMO webinar crop-1

How CDMOs Can Use Data Analytics as a New Source of Revenue

The global biologics market is one of the fastest growing segments of the pharmaceutical industry. But development and production can’t keep pace with discovery. That’s one reason outsourcing to contract development and manufacturing organizations (CDMOs) continues to increase. 

Read the Blog

 

Blog-photo_CDMO-webinar-2-EN-B-00390-Sartorius-1-1

How Data Integrity Helps CDMOs Attract Partners

In spite of the increasing level of importance regulatory agencies place on data integrity and security, many small and large CDMOs don’t have the right systems in place to manage their data properly. How can CDMOs move to the next level and digitalized their data management and processes? 

Read the Blog

SIMCA-in-lab-EN-B-00052-Sartorius-1

How CDMOs Can Implement a Modular PAT Strategy

Process analytical technology (PAT) is playing an increasingly important role in the pharmaceutical and biopharmaceutical industries due to regulatory pressure and the push to reduce costs while managing quality. For CDMOs, any investments into PAT technology must be versatile enough to accommodate a variety of products and processes.

Read the Blog

Trending Technologies that Accelerate Process Development for CDMOs

Trending Technologies that Accelerate Process Development for CDMOs

Adopting a strategy that facilitates rapid and reliable development and scale-up of bioprocesses is an urgently growing priority for contract development and manufacturing organizations (CDMOs). The most successful CDMOs have identified strategies for completing projects efficiently and effectively while incorporating QbD approaches.

Read the Blog

blog109-featured-image-1

How CDMOs Can Digitalize Their Cell and Gene Therapy Processes

The demand for novel biologics is increasing on a global scale, making cell and gene therapies (CGT) among the most rapidly growing areas of the biopharma industry. In order to keep up with the rising demand, CGT developers are turning to CDMOs to outsource both development and manufacturing activities. CDMOs that uses data analytics to address key industry challenges is at a competitive advantage when it comes to process optimization and delivery time for these therapies.

Read the Blog

Multiplexed-Functional-Antibody-Profiling-Using-Advanced-Flow-Cytometry-AdobeStock-414556805-Sartorius

Design of Experiments for Early-Stage Process Development of Antibody-Drug Conjugates: A CDMO Example

Antibody-drug conjugates (ADCs) are a new class of biopharmaceutical drugs that use a chemical linker to bind monoclonal antibodies together with highly potent anti-cancer agents. For CDMOs, ADCs present a lucrative development opportunity, but success hinges on the ability to scale up processes effectively while maintaining Good Manufacturing Practice (GMP) and regulatory compliance. 

Read the Blog

Sartorius_0396_PG14

Leveraging Digitalization: Insights from Biopharma CDMOs  

Contract development and manufacturing organizations (CDMOs) that embrace data analytics are at a competitive advantage when it comes to fulfilling the growing demands for biologics and the push toward digitalization in the pharmaceutical industry.

Read the Blog


Watch a Webinar

Webinar thumb large 750x390_MODDE13_3

How Data Analytics can Boost the Bottom Line at a CDMO

By innovating their service offerings, CDMOs can address some of the major challenges their partners face when deciding to outsource their operations, like loss of control or quality management. In this webinar, we will propose a scenario in which a CDMO can double the return on investment in just one year! 

Watch Now    Download Presentation

OSIsoft and Sartorius Partner to Help CDMOs Leverage their Data

Learn how contract pharma organizations can gain additional insights from their data to become more profitable and increase partner trust. Hear a success story from FUJIFILM Diosynth Biotechnologies, which paired the OSIsoft PI System with advanced data analytics tools to achieve a tenfold optimization in resource expenditure.

Watch Now   Download Presentation

How CDMOs can Adopt a Modular PAT Strategy

When CDMOs investigate the use of PAT they must be assured their ROI, therefore the PAT technology they invest in should be versatile and modular – working with a range of processes and modalities. The Sartorius BioPAT® Spectro Raman tool gives CDMOs working in a high-paced environment the opportunity to unlock the full potential of Raman spectroscopy.

Watch Now  Download Presentation

Putting the “D” in CDMO with Data Analytics and Ambr®

Biopharmaceutical companies have placed an increased reliance on contract development and manufacturing organizations (CDMOs) for all aspects of process development. However, as a CDMO, how can ensure that you’ll be able to meet the aggressive timeline expectations set out by your clients? In this webinar, Sartorius experts will discuss how to accelerate process development timelines. 

Watch Now  Download Presentation

How CDMOs Can Digitalize their Cell and Gene Therapy Processes

One of the most important considerations for companies working in the CGT (cell and gene therapy) field is how to ensure commercial success of the product. By developing a strong relationship with the right CDMO, CGT developers can chart out a development, scale-up, and manufacturing plan that aligns with both their clinical and financial needs.

Watch Now  Download Presentation

Application of DOE (Design of Experiments) to Antibody Drug Conjugates (ADC) Process Development

Find out the Piramal approach to the development of Antibody Drug Conjugates processes. Specifically, it will focus on the use of DOE to develop the key reactive stage of a standard ADC process. The impact of process parameters on product quality attribute, namely Drug-to-Antibody ratio was assessed via full factorial design. The analysis of the design was assessed via Sartorius MODDE® 13 software. The software enabled to modelise the effects of parameters, allowing identification of set points for safe upscaling of the process.

Watch Now Download Sartorius Presentation Download Piramal Presentation

Digitalization and Data Analytics: A CDMOs Perspective - Panel Discussion

Listen to Data Analytics with representatives from across the biopharma industry to share and discuss the opportunities and barriers of digitalization and data analytics at contract development and manufacturing organizations (CDMOs). The panel discussion will address questions like “How does a CDMO approach digitalization?” and “What are some of the special challenges CDMOs face compared to other pharmaceutical industry players?”. At the end of the panel discussion participants are welcome to share their questions and thoughts with the panel.

Watch Now

Get a Free Consultation

Contact Us Now